Related Experiment Video
Updated: May 24, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
Largazole: from discovery to broad-spectrum therapy
1Department of Chemistry, Duke University, Durham, NC 27708, USA. jiyong.hong@duke.edu
Abstract:
The cyclic depsipeptide largazole from a cyanobacterium of the genus Symploca is a marine natural product with a novel chemical scaffold and potently inhibits class I histone deacetylases (HDACs). Largazole possesses highly differential growth-inhibitory activity, preferentially targeting transformed over non-transformed cells. The intriguing structure and biological activity of largazole have attracted strong interest from the synthetic chemistry community to establish synthetic routes to largazole and to investigate its potential as a cancer therapeutic. This Highlight surveys recent advances in this area with a focus on the discovery, synthesis, target identification, structure-activity relationships, HDAC8-largazole thiol crystal structure, and biological studies, including in vivo anticancer and osteogenic activities.
Related Concept Videos
Anthelminthic Agents
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Development of Antibiotic Resistance
Clinical Significance of Antibiotic Resistance
Pharmacogenomics: Identification of New Drug Targets
